表紙
市場調查報告書

神經疾病治療藥的全球市場:產業分析·市場規模·佔有率·成長·趨勢·預測

Neurological Disorder Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027

出版商 Transparency Market Research 商品編碼 930879
出版日期 內容資訊 英文 251 Pages
商品交期: 最快1-2個工作天內
價格
神經疾病治療藥的全球市場:產業分析·市場規模·佔有率·成長·趨勢·預測 Neurological Disorder Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 -2027
出版日期: 2020年03月11日內容資訊: 英文 251 Pages
簡介

本報告提供全球神經疾病治療藥市場調查,提供市場概要,各疾病·藥品級·流通管道·各地區的市場規模的變化與預測,成長率,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 序文

  • 市場定義和範圍
  • 市場區隔
  • 調查目的
  • 調查的重點

第2章 調查手法與假設

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 產品概要
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 市場分析與預測

第5章 市場預測

  • 開發平台分析
  • 疾病的盛行率·罹患率:全體·各國
  • 法規方案

第6章 神經疾病治療藥市場分析與預測:各疾病

  • 簡介和定義
  • 市場規模:各疾病(實際成果值·預測值)
    • 癲癇
    • 阿茲海默症
    • 多發性硬化症
    • 帕金森氏症
    • 腦血管疾病
    • 其他
  • 市場魅力:各疾病

第7章 神經疾病治療藥市場分析與預測:各級藥品

  • 簡介和定義
  • 市場規模:各級藥品(實際成果值·預測值)
    • 抗膽鹼藥
    • 抗癲癇藥
    • 抗精神病藥
    • 止痛藥
    • 安眠劑·鎮靜劑
    • 降壓藥
    • 抗凝固劑
    • 其他
  • 市場魅力:各級藥品

第8章 神經疾病治療藥市場分析與預測:各流通管道

  • 簡介和定義
  • 市場規模:各流通管道(實際成果值·預測值)
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力:各流通管道

第9章 神經疾病治療藥市場分析與預測:各地區

  • 主要調查結果
  • 市場規模:各地區(實際成果值·預測值)
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力:各地區

第10章 北美

第11章 南美

第12章 歐洲

第13章 亞太地區

第14章 中東·非洲

第15章 競爭情形

  • 競爭矩陣
  • 企業的市場佔有率分析
  • 企業簡介
    • Novartis AG
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • AstraZeneca plc
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • 大塚製藥
    • Amgen, Inc.
    • UCB SA
    • Eli Lilly and Company
    • Biogen
目錄
Product Code: TMRGL76505

Scope of the Report

TMR's report on the global neurological disorder drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the global neurological disorder drugs market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global neurological disorder drugs market from 2019 to 2027.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global neurological disorder drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global neurological disorder drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global neurological disorder drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global neurological disorder drugs market.

The report also delves into the competitive landscape of the global neurological disorder drugs market. Key players operating in the global neurological disorder drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global neurological disorder drugs market that have been profiled in this report.

Key Questions Answered:

  • What is the sales/revenue generated by neurological disorder drugs across all regions during the forecast period?
  • What are the opportunities in the global neurological disorder drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which disorder segment is expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Research Objectives and Research Approach

The comprehensive report on the global neurological disorder drugs market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global neurological disorder drugs market in terms of disorder, drug class, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. Such valuable insights enable market stakeholders to make informed business decisions for investment in the global neurological disorder drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurological Disorder Drugs Market

4. Market Overview

  • 4.1. Introduction & Overview
  • 4.2. Product Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Neurological Disorder Drugs Market Analysis and Forecast, 2017-2027

5. Market Outlook

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence & Incidence Rate globally with key countries
  • 5.3. Regulatory Scenario

6. Global Neurological Disorder Drugs Market Analysis and Forecast, by Disorder

  • 6.1. Introduction & Definition
  • 6.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 6.2.1. Epilepsy
    • 6.2.2. Alzheimer Disease
    • 6.2.3. Multiple Sclerosis
    • 6.2.4. Parkinson Disease
    • 6.2.5. Cerebrovascular Diseases
    • 6.2.6. Others
  • 6.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder

7. Global Neurological Disorder Drugs Market Analysis and Forecast, by Drug Class

  • 7.1. Introduction & Definition
  • 7.2. Global Neurological Disorder Drugs Market Value (US$) Forecast, by Drug Class, 2017-2027
    • 7.2.1. Anticholinergic
    • 7.2.2. Antiepileptic
    • 7.2.3. Antipsychotic
    • 7.2.4. Analgesic
    • 7.2.5. Hypnotic & Sedative
    • 7.2.6. Antihypertensive
    • 7.2.7. Anticoagulants
    • 7.2.8. Others
  • 7.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class

8. Global Neurological Disorder Drugs Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Neurological Disorder Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region

10. North America Neurological Disorder Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 10.2.1. Epilepsy
    • 10.2.2. Alzheimer Disease
    • 10.2.3. Multiple Sclerosis
    • 10.2.4. Parkinson Disease
    • 10.2.5. Cerebrovascular Diseases
    • 10.2.6. Others
  • 10.3. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 10.3.1. Anticholinergic
    • 10.3.2. Antiepileptic
    • 10.3.3. Antipsychotic
    • 10.3.4. Analgesic
    • 10.3.5. Hypnotic & Sedative
    • 10.3.6. Antihypertensive
    • 10.3.7. Anticoagulants
    • 10.3.8. Others
  • 10.4. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. North America Neurological Disorder Drugs Market Attractiveness Analysis
    • 10.6.1. By Disorder
    • 10.6.2. By Drug Class
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Neurological Disorder Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 11.2.1. Epilepsy
    • 11.2.2. Alzheimer Disease
    • 11.2.3. Multiple Sclerosis
    • 11.2.4. Parkinson Disease
    • 11.2.5. Cerebrovascular Diseases
    • 11.2.6. Others
  • 11.3. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 11.3.1. Anticholinergic
    • 11.3.2. Antiepileptic
    • 11.3.3. Antipsychotic
    • 11.3.4. Analgesic
    • 11.3.5. Hypnotic & Sedative
    • 11.3.6. Antihypertensive
    • 11.3.7. Anticoagulants
    • 11.3.8. Others
  • 11.4. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Europe Neurological Disorder Drugs Market Attractiveness Analysis
    • 11.6.1. By Disorder
    • 11.6.2. By Drug Class
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 12.2.1. Epilepsy
    • 12.2.2. Alzheimer Disease
    • 12.2.3. Multiple Sclerosis
    • 12.2.4. Parkinson Disease
    • 12.2.5. Cerebrovascular Diseases
    • 12.2.6. Others
  • 12.3. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 12.3.1. Anticholinergic
    • 12.3.2. Antiepileptic
    • 12.3.3. Antipsychotic
    • 12.3.4. Analgesic
    • 12.3.5. Hypnotic & Sedative
    • 12.3.6. Antihypertensive
    • 12.3.7. Anticoagulants
    • 12.3.8. Others
  • 12.4. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis
    • 12.6.1. By Disorder
    • 12.6.2. By Drug Class
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Neurological Disorder Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 13.2.1. Epilepsy
    • 13.2.2. Alzheimer Disease
    • 13.2.3. Multiple Sclerosis
    • 13.2.4. Parkinson Disease
    • 13.2.5. Cerebrovascular Diseases
    • 13.2.6. Others
  • 13.3. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 13.3.1. Anticholinergic
    • 13.3.2. Antiepileptic
    • 13.3.3. Antipsychotic
    • 13.3.4. Analgesic
    • 13.3.5. Hypnotic & Sedative
    • 13.3.6. Antihypertensive
    • 13.3.7. Anticoagulants
    • 13.3.8. Others
  • 13.4. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Latin America Neurological Disorder Drugs Market Attractiveness Analysis
    • 13.6.1. By Disorder
    • 13.6.2. By Drug Class
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Neurological Disorder Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
    • 14.2.1. Epilepsy
    • 14.2.2. Alzheimer Disease
    • 14.2.3. Multiple Sclerosis
    • 14.2.4. Parkinson Disease
    • 14.2.5. Cerebrovascular Diseases
    • 14.2.6. Others
  • 14.3. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 14.3.1. Anticholinergic
    • 14.3.2. Antiepileptic
    • 14.3.3. Antipsychotic
    • 14.3.4. Analgesic
    • 14.3.5. Hypnotic & Sedative
    • 14.3.6. Antihypertensive
    • 14.3.7. Anticoagulants
    • 14.3.8. Others
  • 14.4. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis
    • 14.6.1. By Disorder
    • 14.6.2. By Drug Class
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Competition Matrix
  • 15.2. Market Share Analysis, by Company, 2018
  • 15.3. Company Profiles
    • 15.3.1. Novartis AG
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Company Financials
      • 15.3.1.3. Growth Strategies
      • 15.3.1.4. SWOT Analysis
    • 15.3.2. GlaxoSmithKline plc
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Company Financials
      • 15.3.2.3. Growth Strategies
      • 15.3.2.4. SWOT Analysis
    • 15.3.3. F. Hoffmann-La Roche Ltd.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Company Financials
      • 15.3.3.3. Growth Strategies
      • 15.3.3.4. SWOT Analysis
    • 15.3.4. Pfizer, Inc.
      • 15.3.4.1. Company Overview (HQ, Business Segments)
      • 15.3.4.2. Company Financials
      • 15.3.4.3. Growth Strategies
      • 15.3.4.4. SWOT Analysis
    • 15.3.5. Bayer AG
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Company Financials
      • 15.3.5.3. Growth Strategies
      • 15.3.5.4. SWOT Analysis
    • 15.3.6. Boehringer Ingelheim International GmbH
      • 15.3.6.1. Company Overview (HQ, Business Segments)
      • 15.3.6.2. Company Financials
      • 15.3.6.3. Growth Strategies
      • 15.3.6.4. SWOT Analysis
    • 15.3.7. AstraZeneca plc
      • 15.3.7.1. Company Overview (HQ, Business Segments)
      • 15.3.7.2. Company Financials
      • 15.3.7.3. Growth Strategies
      • 15.3.7.4. SWOT Analysis
    • 15.3.8. Teva Pharmaceutical Industries Ltd.
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Company Financials
      • 15.3.8.3. Growth Strategies
      • 15.3.8.4. SWOT Analysis
    • 15.3.9. Merck & Co., Inc.
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Company Financials
      • 15.3.9.3. Growth Strategies
      • 15.3.9.4. SWOT Analysis
    • 15.3.10. Otsuka Pharmaceutical Co., Ltd.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Company Financials
      • 15.3.10.3. Growth Strategies
      • 15.3.10.4. SWOT Analysis
    • 15.3.11. Amgen, Inc.
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Company Financials
      • 15.3.11.3. Growth Strategies
      • 15.3.11.4. SWOT Analysis
    • 15.3.12. UCB S.A.
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Company Financials
      • 15.3.12.3. Growth Strategies
      • 15.3.12.4. SWOT Analysis
    • 15.3.13. Eli Lilly and Company
      • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.13.2. Company Financials
      • 15.3.13.3. Growth Strategies
      • 15.3.13.4. SWOT Analysis
    • 15.3.14. Biogen
      • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.14.2. Company Financials
      • 15.3.14.3. Growth Strategies
      • 15.3.14.4. SWOT Analysis

List of Tables

  • Table 01: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 03: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 04: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 05: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 06: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 07: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 08: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 09: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 10: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 11: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 12: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 13: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 14: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 15: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 16: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 17: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 18: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 19: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 20: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 21: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Disorder, 2017-2027
  • Table 22: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 23: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 24: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

List of Figures

  • Figure 01: Global Neurological Disorder Drugs Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
  • Figure 02: Global Neurological Disorder Drugs Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 03: Global Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 04: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Epilepsy, 2017-2027
  • Figure 05: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alzheimer's Disease, 2017-2027
  • Figure 06: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parkinson's Disease, 2017-2027
  • Figure 07: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multiple Sclerosis, 2017-2027
  • Figure 08: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cerebrovascular Diseases, 2017-2027
  • Figure 09: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 10: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 11: Global Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 12: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticholinergic, 2017-2027
  • Figure 13: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antiepileptic, 2017-2027
  • Figure 14: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antipsychotic, 2017-2027
  • Figure 15: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Analgesic, 2017-2027
  • Figure 16: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hypnotic & Sedative, 2017-2027
  • Figure 17: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antihypertensive, 2017-2027
  • Figure 18: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticoagulant, 2017-2027
  • Figure 19: Global Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 20: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 21: Global Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 22: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacies, 2017-2027
  • Figure 23: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2017-2027
  • Figure 24: Global Neurological Disorder Drugs Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2017-2027
  • Figure 25: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 26: Global Neurological Disorder Drugs Market, by Region, 2018 and 2027
  • Figure 27: Global Neurological Disorder Drugs Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 28: North America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 29: North America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 30: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 31: North America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 32: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 33: North America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 34: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 35: North America Neurological Disorder Drugs Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 36: North America Neurological Disorder Drugs Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 37: Europe Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 38: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 39: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 40: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 41: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 42: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 43: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 44: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 45: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 46: Asia Pacific Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 47: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 48: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 49: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 50: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 51: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 52: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 53: Asia Pacific Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 54: Asia Pacific Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 55: Latin America Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 56: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 57: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 58: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 59: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 60: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 61: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 62: Latin America Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 63: Latin America Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 64: Middle East & Africa Neurological Disorder Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 65: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2018 and 2027
  • Figure 66: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2019-2027
  • Figure 67: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 68: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 69: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2027
  • Figure 70: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 71: Middle East & Africa Neurological Disorder Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 72: Middle East & Africa Neurological Disorder Drugs Market Attractiveness Analysis, by Country/Sub-region, 2019-2027